The allogeneic t cell therapies global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Allogeneic T Cell Therapies Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The allogeneic T cell therapies market size has grown strongly in recent years. It will grow from $1.06 billion in 2023 to $1.16 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to regulatory approvals, increasing cancer prevalence, rising clinical trials, government funding, and a growing geriatric population.
The allogeneic T cell therapies market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to expanding indications, rising demand for cell-based immunotherapies, growing awareness about advanced therapies, increasing healthcare expenditure, and supportive reimbursement policies. Major trends in the forecast period include advancement in research and development activities, personalized medicine, off-the-shelf therapies, global market expansion, strategic partnerships, and regulatory landscape evolution.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/allogeneic-t-cell-therapies-global-market-report
Scope Of Allogeneic T Cell Therapies Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Allogeneic T Cell Therapies Market Overview
Market Drivers –
The increasing cases of cancer are expected to propel the growth of the allogeneic T cell therapies market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Cancer cases are rising due to factors such as longer lifespans, lifestyle changes, environmental exposures, infections, genetic factors, and changes in reproductive patterns, which collectively contribute to a higher incidence and detection of the disease. Allogeneic T cell therapies are used in cancer patients to target and kill cancer cells by infusing genetically engineered donor T cells that recognize specific tumor antigens. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, there were about 18.1 million cancer survivors in the United States. This figure is projected to rise to 22.5 million by 2032. By 2040, it’s expected that the number of new cancer cases each year will reach 29.9 million, with cancer-related deaths estimated to increase to 15.3 million. Therefore, the increasing cases of cancer drive the allogeneic T cell therapies market.
Market Trends –
Major companies operating in the allogeneic T cell therapies market are focused on developing innovative chimeric antigen receptor (CAR) T-cell therapy initiatives to enhance treatment efficacy and expand therapeutic options. Innovative chimeric antigen receptor (CAR) T-cell therapy initiatives refer to advanced approaches designed to enhance the effectiveness, accessibility, and delivery of CAR T-cell treatments for cancer. For instance, in October 2022, Allogene Therapeutics Inc., a US-based biotechnology company, launched CAR T Together, an innovative initiative to address the challenges of delivering and accessing CAR T therapies. The program focuses on simplifying clinical trial enrollment and fostering collaboration among oncologists to accelerate the development of allogeneic CAR T therapies. Unlike autologous therapies, which are customized from a patient’s own cells, allogeneic therapies use T cells from healthy donors, enabling more efficient manufacturing processes.
The allogeneic T cell therapies market covered in this report is segmented –
1) By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies, T Cell Receptor (TCR) Therapies, Other Product Types
2) By Antigen Type: CD 19, CD 20, Egfrvlll, GD2, CD22, CD30, CD33, Meso, HER1, Other Antigen Types
3) By Therapeutics Indications: Cancer, Autoimmune Diseases, Infectious Diseases, Others Therapeutics Indications
4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Get an inside scoop of the allogeneic t cell therapies market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=18952&type=smp
Regional Insights –
North America was the largest region in the allogeneic T cell therapies market in 2023. The regions covered in the allogeneic T cell therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the allogeneic t cell therapies market are Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Immatics NV, Sangamo Therapeutics Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Sorrento Therapeutics Inc., Autolus Therapeutics Plc, MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Enlivex Therapeutics Ltd., Cellectis SA, Adaptimmune Therapeutics Plc, Medigene AG, Celyad Oncology SA, Allogene Therapeutics Inc., Bellicum Pharmaceuticals Inc.
Table of Contents
1. Executive Summary
2. Allogeneic T Cell Therapies Market Report Structure
3. Allogeneic T Cell Therapies Market Trends And Strategies
4. Allogeneic T Cell Therapies Market – Macro Economic Scenario
5. Allogeneic T Cell Therapies Market Size And Growth
…..
27. Allogeneic T Cell Therapies Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
